{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:40:52Z","timestamp":1768016452828,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.eplepsyres.2017.10.021","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T18:18:35Z","timestamp":1509819515000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials"],"prefix":"10.1016","volume":"139","author":[{"given":"Gregory","family":"Krauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Biton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay H.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Elger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcio","family":"Soares da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Grinnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pediatrneurol.2004.04.012","article-title":"Topiramate slow dose titration: improved efficacy and tolerability","volume":"31","author":"Albsoul-Younes","year":"2004","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0015","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","article-title":"Comparison and predictors of rash associated with 15 antiepileptic drugs","volume":"68","author":"Arif","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1345\/aph.10093","article-title":"Topiramate titration and tolerability","volume":"35","author":"Biton","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eplepsyres.2013.08.021","article-title":"Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures","volume":"107","author":"Biton","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0045","first-page":"112","article-title":"Safety and efficacy of eslicarbazepine acetate treatment in elderly patients","volume":"55","author":"Costa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2015.02.025","article-title":"Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy","volume":"27","author":"Dash","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-0404.2011.01619.x","article-title":"Minimizing pharmacodynamic interactions of high doses of lacosamide","volume":"125","author":"Edwards","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1684\/epd.2012.0510","article-title":"Antiepileptic drug trials: the view from the clinic","volume":"14","author":"Faught","year":"2012","journal-title":"Epileptic. Disord."},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2017.10.021_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","volume":"62","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2017.10.021_bib0090","first-page":"S37","article-title":"Therapeutic safety monitoring: what to look for and when to look for it","volume":"41","author":"Harden","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/seiz.2001.0605","article-title":"Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial","volume":"11","author":"Korean Topiramate Study Group","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0110","series-title":"Prescribing Information","author":"Lamotrigine (Lamictal)","year":"2014"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0115","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","article-title":"Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments","volume":"52","author":"Luoni","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0120","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00023210-200115080-00004","article-title":"Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation","volume":"15","author":"Perucca","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0130","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0135","article-title":"Antiepileptic drugs and hyponatremia","author":"Sachdeo","year":"2016","journal-title":"Neurol. Rev."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0140","series-title":"Epilepsy: A Comprehensive Textbook","article-title":"Dose-related side effects","author":"Schmidt","year":"2008"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0145","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.104","article-title":"An investigation of the incidence and time to onset of adverse events associated with eslicarbazepine acetate adjunct treatment: an integrated analysis of two double-blind placebo-controlled trials (P06.104)","volume":"78","author":"Sperling","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0155","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0160","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0165","series-title":"Efficacy of Eslicarbazepine Acetate Vs Controlled-release Carbamazepine as Monotherapy in Patients with Newly Diagnosed Partial-onset Seizures","author":"Trinka","year":"2016"},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ane.12015","article-title":"Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?","volume":"126","author":"Trinka","year":"2012","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0175","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.10.021_bib0180","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117301213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117301213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:37:25Z","timestamp":1760276245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121117301213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":36,"alternative-id":["S0920121117301213"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.10.021","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}